Emet Surgical Aspires to Improve Surgery Outcomes by Enabling True Collaboration Between Cancer Surgeons and Pathologists

DENVER & TEL AVIV--(BUSINESS WIRE)--Emet Surgical, developers of innovative tools to improve surgery outcomes, launched today with the goal of providing better ways for cancer surgeons and pathologists to collaborate.

“I know from personal experience that getting a cancer diagnosis is an incredibly traumatic experience but is compounded even more so when the patient learns their first surgery was incomplete and a re-surgery is required”

Medical literature points to poor communication between the surgeon and the pathologist as a significant problem, leading to incomplete tumor excisions, and resulting in the need for a second or “re-surgery.” To minimize the need for repeat surgeries, it is important for the surgeon and the pathologist to communicate effectively throughout the process. Traditional tumor margin marking tools, marking only the tumor, puts constraints on their ability to effectively communicate orientation and location details with one another.

In consultation with medical professionals in the US and Israel, the company has developed solutions that serve as the foundation for more efficient and effective surgeon and pathologist communication. TrueMargin™, an investigational product, currently awaiting U.S. FDA 510(k) clearance, is an easy-to-use tumor margin-marking system that requires no new tools and no new training for surgeons and can be simply added to the surgical and pathology workflows.

TrueMargin overcomes conventional tumor marking that is often incomplete by providing specific in-vivo and ex-vivo location and orientation details. The result aligns both the surgical and pathology teams and enables effective and specific communication. Healthcare systems will achieve measurable productivity improvements and cost savings with the use of TrueMargin.

“I know from personal experience that getting a cancer diagnosis is an incredibly traumatic experience but is compounded even more so when the patient learns their first surgery was incomplete and a re-surgery is required,” said Bob Witkow, founder and CEO of Emet Surgical. “What I found true in medical literature going back over 75-years, is that ineffective communication between the surgeon and pathologist oftentimes contributes to incomplete cancer excisions, requiring a re-surgery. I was determined to find a solution that would minimize these types of situations from occurring for others and hopefully make an already traumatizing situation less so.”

Emet Surgical has filed multiple patent applications for tools, how they are produced, and how they are packaged. The company’s goal is to secure FDA 510(k) clearance as well as other country registrations during the third quarter of this year, at which point, it will begin shipping TrueMargin in volume. In addition to its first investigational product, Emet Surgical has additional products ready for introduction by the end of the year pending regulatory approval.

Executive leadership from Emet Surgical will be attending The American Society of Breast Surgeons Annual Meeting in Boston April 26-30. Those interested in meeting with Emet Surgical at the conference or wanting to know more about TrueMargin products when they receive approval can sign up on the company’s website at https://www.emetsurgical.com.

About Emet Surgical

Taking its name from the Hebrew word for “truth,” Emet Surgical is enabling true surgeon/pathologist collaboration. Emet Surgical’s TrueMargin™ tumor margin marking tools, now under regulatory review, provide surgeons and pathologists with specific in-vivo and ex-vivo tumor margin, location, and orientation details. TrueMargin tools for open, minimally invasive, and robotic procedures enable communication and collaboration not seen before. Founded in 2022, the company is headquartered in Denver with significant operations in Tel Aviv and Haifa, Israel. Additional information is available at www.EmetSurgical.com or by emailing Info@EmetSurgical.com.

Contacts

MEDIA CONTACT:
Mark Smith, JPR Communications
818-398-1424